Interv Akut Kardiol. 2023;22(1):44-48 | DOI: 10.36290/kar.2023.007

Catheter-based treatment of residual mitral regurgitation after MitraClip implantation: a case report

Jaroslav Januška, Miroslav Hudec, Libor Gajdušek, Miroslav Dorda, Martin Urban, Leoš Derych, Libor Škňouřil
Kardiocentrum, Nemocnice Agel Třinec-Podlesí, a. s.

Residual mitral regurgitation after MitraClip implantation is a progressively increasing problem. Progression of left ventricular dysfunction, deterioration of valvular and subvalvular function, or suboptimal MitraClip implantation all increase the risk of progression of residual regurgitation. In this case report, we describe a patient with severe degenerative mitral regurgitation managed with repeated implantation of MitraClips followed by implantation of Amplatzer Vascular Plugs between the clips, with a significant reduction in regurgitation and functional normalization of the patient's complaints.

Keywords: mitral valve, MitraClip, residual regurgitation, Amplatzer Vascular Plug.

Accepted: March 27, 2023; Published: April 12, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Januška J, Hudec M, Gajdušek L, Dorda M, Urban M, Derych L, Škňouřil L. Catheter-based treatment of residual mitral regurgitation after MitraClip implantation: a case report. Interv Akut Kardiol. 2023;22(1):44-48. doi: 10.36290/kar.2023.007.
Download citation

References

  1. Iliadis C, Baldus S, Kalbacher D, et al. Impact of left atrial diameter on outcome in patients undergoing edge­‑to­‑edge mitral valve repair: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) registry. Eur J Heart Fail. 2020;22(7):1202-1210. Go to original source... Go to PubMed...
  2. Taramasso M, Alessandrini H, Kuwata S, et al. Multicenter Experience With Treatment of Residual Mitral Regurgitation After MitraClip Implantation Using Amplatzer Closure Device: Mid­‑Term Results. JACC Cardiovasc Interv. 2017;10(9):966-970. Go to original source... Go to PubMed...
  3. Beohar N, Ailawadi G, Kotinkaduwa LN, et al. Impact of baseline renal dysfunction on cardiac outcomes and end­‑stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial. Eur Heart J. 2022;43(17):1639-1648. Go to original source... Go to PubMed...
  4. Agricola E, Ielasi A, Oppizzi M, et al. Long­‑term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. Eur J Heart Fail. 2009;11(6):581-7. Go to original source... Go to PubMed...
  5. Eggebrecht H, Schelle S, Puls M, et al. Risk and outcomes of complications during and after MitraClip implantation: Experience in 828 patients from the German TRAnscatheter mitral valve interventions (TRAMI) registry. Catheter Cardiovasc Interv. 2015;86(4):728-35. Go to original source... Go to PubMed...
  6. Garcia­‑Sayan E, Raghunathan D, Li FM, et al. Initial experience with the fourth generation MitraClip™: Outcomes, procedural aspects, and considerations for device selection. Catheter Cardiovasc Interv. 2021;98(4):E626-E636. Go to original source... Go to PubMed...
  7. Roques F, Michel P, Goldstone AR, et al. The logistic EuroSCORE. Eur Heart J. 2003;24(9):881-2. Go to original source... Go to PubMed...
  8. Hemmann K, Sirotina M, De Rosa S, et al. The STS score is the strongest predictor of long­‑term survival following transcatheter aortic valve implantation, whereas access route (transapical versus transfemoral) has no predictive value beyond the periprocedural phase. Interact Cardiovasc Thorac Surg. 2013;17(2):359-64. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.